Education
About Us
Working with TipRanks
Follow Us
Daily Stock Ratings & Price Targets
Analyst Performance
Any
Analyst Rating
Any
Upside / Downside
Any
Action
Any
Market Cap
Any
Analyst & Firm | Company | Price | Rating & Price Target | Upside / Downside | Success Rate | Average Return | Action | Date | Article |
|---|---|---|---|---|---|---|---|---|---|
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $165→$160 | ― | 20.20% | Reiterated | ||||
 | Chemomab Therapeutics | BUY $11→$10 | ― | -19.70% | Reiterated | Chemomab Therapeutics price target lowered to $10 from $11 at Oppenheimer | |||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $530→$560 | ― | 18.40% | Reiterated | ||||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $83→$65 | ― | 13.90% | Reiterated | ||||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $350→$365 | ― | 15.70% | Reiterated | ||||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $175 | ― | 14.20% | Reiterated | ||||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $235→$270 | ― | 16.40% | Reiterated | ||||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $250 | ― | 8.20% | Reiterated | ||||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $190→$176 | ― | 16.40% | Reiterated | ||||
| Crispr Therapeutics AG | BUY $79 | ― | -12.10% | Reiterated | Bank of America Securities Sticks to Its Buy Rating for Crispr Therapeutics AG (CRSP) | |||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $17 | ― | 7.30% | Reiterated | ||||
| AbCellera Biologics | BUY $28→$10 | ― | -5.90% | Reiterated | Truist Financial Remains a Buy on AbCellera Biologics (ABCL) | |||
 | Doximity | HOLD $58→$52 | ― | -15.30% | Reiterated | Truist Financial Remains a Hold on Doximity (DOCS) | |||
| P3 Health Partners | HOLD $12.5→$0.25 | ― | -6.60% | Reiterated | TD Cowen Sticks to Its Hold Rating for P3 Health Partners (PIII) | |||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $90 | ― | 10.30% | Reiterated | ||||
| Urogen Pharma | BUY $35 | ― | -17.60% | Reiterated | Urogen Pharma (URGN) Receives a Buy from TD Cowen | |||
| KE Holdings Inc. Sponsored ADR Class A | BUY $24.5→$23 | ― | -17.00% | Upgraded | KE Holdings upgraded to Buy from Neutral at UBS | |||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $105→$115 | ― | 11.60% | Reiterated | ||||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $65→$70 | ― | 4.00% | Reiterated | ||||
 | Brunswick | HOLD $56→$60 | ― | -0.40% | Reiterated | Brunswick price target raised to $60 from $56 at Baird | |||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $9 | ― | 10.40% | Reiterated | ||||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $10 | ― | 31.70% | Reiterated | ||||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | HOLD $1,250→$1,200 | ― | 0.20% | Reiterated | ||||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $50 | ― | 0.20% | Reiterated | ||||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $26 | ― | 0.20% | Reiterated | ||||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | HOLD $26 | ― | 0.20% | Reiterated | ||||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $85 | ― | 4.70% | Reiterated | ||||
| Gambling.com | BUY $18 | ― | 0.00% | Reiterated | Stifel Nicolaus Reaffirms Their Buy Rating on Gambling.com (GAMB) | |||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $161→$171 | ― | 17.30% | Reiterated | ||||
| Opus Genetics | BUY $8→$5 | ― | -1.90% | Reiterated | JonesTrading Reaffirms Their Buy Rating on Opus Genetics (IRD) | |||
 | vTv Therapeutics | BUY $35 | ― | -25.60% | Reiterated | Analysts Offer Insights on Healthcare Companies: vTv Therapeutics (NASDAQ: VTVT) and Precision BioSciences (NASDAQ: DTIL) | |||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $1,200→$1,300 | ― | 4.60% | Reiterated | ||||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | HOLD $501→$514 | ― | 13.10% | Reiterated | ||||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $303→$335 | ― | 11.40% | Reiterated | ||||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $147→$142 | ― | 12.60% | Reiterated | ||||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $146→$141 | ― | 9.90% | Reiterated | ||||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $100→$110 | ― | 15.40% | Reiterated | ||||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | HOLD $10→$9 | ― | 9.70% | Reiterated | ||||
| Cytek Biosciences | BUY $6→$4 | ― | -16.40% | Reiterated | Cytek Biosciences price target lowered to $4 from $6 at Stephens | |||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $24 | ― | 33.60% | Reiterated | ||||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $210 | ― | 26.40% | Reiterated | ||||
 | Fiserv | BUY $223→$194 | ― | -8.30% | Reiterated | New Buy Rating for Fiserv (FI), the Technology Giant | |||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $30→$33 | ― | 10.80% | Reiterated | ||||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $24→$23 | ― | 13.00% | Reiterated | ||||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $20→$17 | ― | 13.00% | Reiterated | ||||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $14→$16 | ― | 8.80% | Reiterated | ||||
 | Canadian Solar | SELL $8→$9 | ― | -0.40% | Reiterated | Goldman Sachs Keeps Their Sell Rating on Canadian Solar (CSIQ) | |||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $3 | ― | 3.80% | Reiterated | ||||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $515 | ― | 28.80% | Reiterated | ||||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $210→$230 | ― | 12.60% | Reiterated |
Rows:
